retifanlimab + gemcitabine + cisplatin

This combination regimen consists of **retifanlimab** (a monoclonal antibody), **gemcitabine** (a nucleoside analog antimetabolite), and **cisplatin** (a platinum-based DNA crosslinking agent), used together for cancer chemotherapy. **Retifanlimab** is an anti-PD-1 immune checkpoint inhibitor that blocks the programmed death-1 (PD-1) receptor, restoring anti-tumor immunity[3]. **Gemcitabine** inhibits DNA synthesis by incorporating into DNA as a nucleoside analog, leading to apoptosis in rapidly dividing tumor cells[5]. **Cisplatin** causes DNA crosslinking and damage, preventing replication and leading to cell death[5]. This combination leverages immune-mediated and cytotoxic mechanisms against malignancy. While combinations of gemcitabine + cisplatin are standard in multiple cancers (including biliary tract, lung, bladder, pancreas)[2][5][6][8], addition of retifanlimab introduces checkpoint blockade immunotherapy (used with platinum doublets in anal cancer and being tested in other solid tumors)[3]. Retifanlimab is developed and manufactured by Incyte[3]. Gemcitabine is a small molecule generic agent originally developed by Eli Lilly. Cisplatin is generic, originally developed by Bristol Myers Squibb.

Other names

retifanlimab + gemcitabine + cisplatin